LDS/Medical Tests/Small Lymphocytic Lymphoma, FISH

Small Lymphocytic Lymphoma, FISH

Two major types of lymphocytes normally exist, B-lymphocytes and T-lymphocytes. These are small-sized white blood cells responsible for the body’s immune responses. B-lymphocytes are a major component of humoral immunity and have a role in producing immunoglobulins (antibodies) by differentiating into plasma cells. T-lymphocytes are responsible for cell-mediated immune response and killing of intracellular pathogens.

Excessive clonal production of these lymphocytes is referred to as lymphocytic leukemia, which are further characterized as acute (proliferation of primitive undifferentiated cells with rapid clinical progression) or chronic (accumulation of matures appearing cell, and a chronic course).

B-cell chronic lymphocytic leukemia (CLL) is a disease of older individuals in which the leukemic cells lose the ability to undergo apoptosis and so gradually accumulate in the blood, bone marrow and other tissues, ultimately causing organ failure and death. By definition this ‘leukemic’ proliferation begins in the bone marrow and is typically first detected by increased number of small mature appearing lymphocytes in the peripheral blood. Small lymphocytic lymphoma (SLL) composed of the same cells but originates in lymph nodes or spleen, hence the term ‘lymphoma’ is used. Over time, SLL involves the other organs the bone marrow, and appears in the peripheral blood. If the disorder is first detected in the blood and bone marrow it is CLL, and when first detected in enlarged lymph nodes it is diagnosed as SLL. With time, however, these two entities overlap in their tissue distribution and it may be impossible to determine which site the clonal cells originated in. In this circumstance the disorder is termed CLL/SLL.

B-cell CLL/SLL is the most common lymphoproliferative disorder in western countries and accounts for 25-35% of U.S leukemias. Most cases originate as CLL and only about 10% arise in lymph nodes. Men are affected more often with a M:F ratio of 1.2-1.7:1. The incidence among men and women in the U.S are 6.75 and 3.65 cases per 100,000 per year respectively. The median age at diagnosis is 70 years and there ius a higher incidence in white Americans as compared to African Americans or Asian pacific islanders.

B-cell CLL is diagnoses when there is > 5000 B-cells per uL although much higher counts (e.g.> 100,000/uL) can be seen. The cells can be shown to be clonal by flow cytometry by the presence of B-cell surface markers (CD19, CD20, CD23) and aberrant expression of the T-cell marker CD-5, and low levels of monoclonal surface Ig with a single light chain type. The NCCN recommends evaluating the cells in patients with CLL or SLL for del(17p), +12, del(11q), del(13q) and t(11:14) by FISH, TP53 mutations by molecular methods, IGHV mutational status as well as CpG-stimulated cytogenetic evaluation in the initial workup of patients. Both del(17p) and TP53 mutations suggest a worse response to chemotherapy versus targeted therapy. IGHV mutations are associated with higher risk of relapse after chemotherapy or bone marrow transplant and shorted survival. ZAP-70 and CD38 expression are sometimes used as surrogates for IGHV testing but do not correlate exactly.

  • Useful in the diagnosis of small lymphocytic lymphoma
  • Helpful in differentiating CLL/SLL from other similar appearing disorders like mantle cell lymphoma
  • Therapy selection and monitoring
  • Disease management and prediction
An increased percentage of cells than the reference range for the specified clone signifies neoplastic changes. The percentage of cells within the normal reference range indicates the absence of neoplastic clones of the targeted cytogenetic abnormality.

Negative for neoplastic changes

Fluorescent in-situ hybridization (FISH).

Tissue (Lymph node or solid tumor). Paraffin-block of tissue fixed in formalin is preferred.

Histological slides of at least 5-micron thickness with an additional slide stained with hematoxylin and eosin are acceptable.

CBC, peripheral blood smear, bone marrow examination, immunophenotyping by flow cytometry, Leukemia and Lymphoma by next-generation sequencing (NGS), immunohistochemistry and special stain for specific markers.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login